- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
TransScan wins additional FDA clearance
Mammography firm TransScan Research and Development has received clearance from the Food and Drug Administration for a premarket approval supplement for its TS-2000 electrical impedance breast scanning system that covers improvements in the unit’s
Mammography firm TransScan Research and Development has received clearance from the Food and Drug Administration for a premarket approval supplement for its TS-2000 electrical impedance breast scanning system that covers improvements in the units design and operation. The Ramsey, NJ, firm announced the news along with Siemens Medical Systems of Iselin, NJ, with which it signed a marketing agreement last December (SCAN 1/7/99).
A hand-held device that measures electrical impedance in breast tissue, TS-2000 includes a ground-electrode cylinder that patients hold as it transmits a low-voltage electrical signal through the body. A probe placed on the breast and moved across the skin measures changes in the signal. In real-time, the probe produces images on a computer screen that reveal differences in the electrical impedance between malignant tumor tissue and normal tissue.
The unit was initially cleared by the FDA in April for use as an adjunct to mammography for follow-up exams in patients with equivocal mammograms (SCAN 4/28/99). TransScan hopes that the cleared PMA supplement will pave the way for the unit to be used for other types of cancer.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
